Merck, Eisai’s 007 goes down as Keytruda-Lenvima combo fails in newly diagnosed lung cancer
Merck & Co. isn’t resting on Keytruda’s laurels. But an attempt to improve on the undoubtful cancer immunotherapy king with another agent has failed in a 007 miss...
Continue Reading →
